US Stem Cell Inc (USRM)
0.0001
USD |
OTCM |
Apr 24, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 0.0642M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -96.97% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 100.00% |
Profile
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. |
URL | http://www.us-stemcell.com |
Investor Relations URL | N/A |
HQ State/Province | Florida |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. |
URL | http://www.us-stemcell.com |
Investor Relations URL | N/A |
HQ State/Province | Florida |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |